Skip to main content
Equibles
BGLC logo

BGLC · BioNexus Gene Lab Corp · Metrics

Track BGLC — free

Use BGLC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BGLC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.21 -0.02 (-1.86%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.53M
Shares
2.93M
Volume · Oct 20 1043 Avg daily vol (3M) 11.4K

BGLC metrics

64 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.21
Market cap
$3.53M

Price action

20 metrics
Price change (1W)
-11.6%
Price change (30D)
-18.1%
Price change (3M)
-26.5%
Price change (6M)
-46.1%
Price change (YTD)
-68.9%
Price change (1Y)
-76.1%
Trailing year
Price change (5Y)
—
52-week high
$5.48
52-week low
$1.20
Change from 52-week high
-77.6%
Change from 52-week low
+2.3%
Annualized volatility
68.9%
Annualized volatility (3M)
68.5%
Beta
1.4
RSI (14D)
41.8
Price vs SMA 50
-14.5%
Price vs SMA 200
-42.1%
Avg volume (3M)
11,417
Relative volume
0.2
Average dollar volume
$16,233

Company

3 metrics
Sector
Basic Materials
Industry
Specialty Chemicals
Shares outstanding
2.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.1×
reciprocal yield 88.8%
P / book
0.5
reciprocal yield 221.0%
FCF yield
-24.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-73.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
12.3%
Operating margin
-81.8%
Trailing 12 months
Net margin
-82.4%
Gross profit (TTM)
$385,894
Operating profit (TTM)
−$2.56M
Net income (TTM)
−$2.58M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-27.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.56

Growth

11 metrics
Revenue growth YoY
-96.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.13M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.5%
Year over year · more shares
Revenue CAGR (3Y)
-12.1%
Revenue CAGR (5Y)
-8.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-33.1%
Return on assets
-29.5%
Debt / equity
—
Current ratio
6.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$853,600
Quick ratio
5.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.23M
Latest balance sheet
Cash & equivalents
$1.23M
Total assets
$8.73M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$846,565
Capital expenditures (TTM)
$7,035
R&D (TTM)
$54,132
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
1.7%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
3
13F filer change QoQ
+1
Institutional ownership
0.5%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+6,100.4%
Holder tenure
1.0
Price vs estimated holder cost
-10.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
0.3%
Latest settlement · 1.5 days to cover
Days to cover
1.5d
Short-squeeze score
30 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1737523 CUSIP 090628306 Visit website Investor relations